Syndax Pharmaceuticals

SNDX

Market cap $2.14B

NEW YORK, April 03, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on April 1, 2026, the Company granted inducement awards to purchase up to 228,500 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

DAFNA Capital Management sold 222,847 SNDX shares in the fourth quarter for an estimated roughly $4 million. Meanwhile, the quarter-end position value decreased by $1.87 million, reflecting both trading and price movements.

Kynam Capital reduced its Syndax Pharmaceuticals stake by 469,041 shares in the fourth quarter; the estimated trade size was $8.18 million based on average closing prices for the quarter. Meanwhile, the quarter-end position value increased by $38.07 million, reflecting both trading and share price changes.

Syndax Pharma delivered robust Q4 2025 results, with sales of $68.7 million (+794.5% YoY), driven by Revuforj and Niktimvo. Revuforj's rapid commercialization and label expansion position SNDX to access a $5 billion+ AML market, with 1L Phase 3 trials as a major catalyst. Niktimvo's strong launch in GVHD and operational leverage support increasing collaboration revenue, with potential market doubling via frontline studies.

Sphera Funds added 374,847 shares of Syndax Pharmaceuticals in the fourth quarter. The quarter-end position value rose by $10.06 million, reflecting both trading and price movement.

Syndax Pharmaceuticals, Inc. (SNDX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Wall Street is turning constructive on three clinical-stage biotechs simultaneously, each sitting at the edge of a binary catalyst.

NEW YORK, March 04, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on March 1, 2026, the Company granted inducement awards to purchase up to 81,600 shares of common stock to three new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

Syndax Pharmaceuticals, Inc. (SNDX) Q4 2025 Earnings Call Transcript

Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $1.1 per share a year ago.